Toceranib is a small molecule, multi-targeted receptor tyrosine kinase inhibitor that is structurally related to sunitinib . It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit. Moveover, toceranib blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death. It is active in vivo and is commonly used against solid tumors in dogs.
